Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

[1]  L. Cardon,et al.  Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean Males , 2011, PloS one.

[2]  Simon C. Potter,et al.  The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study , 2011, PLoS genetics.

[3]  T. Assimes,et al.  Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies , 2011, The Lancet.

[4]  Jie Cao,et al.  PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis. , 2010, Thrombosis research.

[5]  Daniel L. Koller,et al.  Association of the Vitamin D Metabolism Gene CYP24A1 With Coronary Artery Calcification , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Muredach P. Reilly,et al.  Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. , 2010, The American journal of cardiology.

[7]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[8]  S. Johnston,et al.  Association of Carotid Plaque Lp-PLA2 with Macrophages and Chlamydia pneumoniae Infection among Patients at Risk for Stroke , 2010, PloS one.

[9]  Jackie A Cooper,et al.  PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry , 2010, Circulation.

[10]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[11]  G. Ginsburg,et al.  Genome-Wide Association Study of Lp-PLA2 Activity and Mass in the Framingham Heart Study , 2010, PLoS genetics.

[12]  Daniel L. Koller,et al.  Association of the Vitamin D Metabolism Gene CYP24A1 With Coronary Artery Calcification , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[13]  G. Ginsburg,et al.  Genome-Wide Association Study of Lp-PLA 2 Activity and Mass in the Framingham Heart Study , 2010 .

[14]  T. Miyata,et al.  Association of PLA2G7 polymorphisms with carotid atherosclerosis in hypertensive Japanese , 2009, Hypertension Research.

[15]  R. Wilensky,et al.  Lipoprotein-associated phospholipase A2 and atherosclerosis , 2009, Current opinion in lipidology.

[16]  M. Reilly,et al.  Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans , 2009, Diabetes.

[17]  Shahrul Mt-Isa,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[18]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[19]  A. Tselepis,et al.  The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. , 2009, Biochimica et biophysica acta.

[20]  W. Koenig,et al.  Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence , 2009, Cardiovascular Drugs and Therapy.

[21]  K. Shianna,et al.  Tissue-Specific Genetic Control of Splicing: Implications for the Study of Complex Traits , 2008, PLoS biology.

[22]  Mark I. McCarthy,et al.  Concept, Design and Implementation of a Cardiovascular Gene-Centric 50 K SNP Array for Large-Scale Genomic Association Studies , 2008, PloS one.

[23]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[24]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[25]  J. H. Lee,et al.  Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. , 2008, The American journal of clinical nutrition.

[26]  M. Corson,et al.  Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. , 2008, The American journal of cardiology.

[27]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[28]  M. Hanefeld,et al.  The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.

[29]  E. Barrett-Connor,et al.  Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. , 2008, Journal of the American College of Cardiology.

[30]  J. Cooper,et al.  Distinct Roles for Arp2/3 Regulators in Actin Assembly and Endocytosis , 2008, PLoS biology.

[31]  Alberto Mantovani,et al.  Macrophage activation and polarization. , 2008, Frontiers in bioscience : a journal and virtual library.

[32]  M. Reilly,et al.  Innate immunity modulates adipokines in humans. , 2007, The Journal of clinical endocrinology and metabolism.

[33]  G. Berglund,et al.  The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. , 2007, Atherosclerosis.

[34]  R. Virmani,et al.  Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[35]  A. Zalewski,et al.  Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  M. Reilly,et al.  An Inflammatory Cascade Leading to Hyperresistinemia in Humans , 2004, PLoS medicine.

[37]  A. Localio,et al.  Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[38]  D. Nyholt.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[39]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[40]  H. Bang,et al.  Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study , 2004 .

[41]  G. Zimmerman,et al.  Molecular characterization of the constitutive expression of the plasma platelet-activating factor acetylhydrolase gene in macrophages. , 2003, The Biochemical journal.

[42]  A. Localio,et al.  C-Reactive Protein and Coronary Artery Calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[44]  David B. Leake,et al.  Inhibition of lipoprotein‐associated phospholipase A2 diminishes the death‐inducing effects of oxidised LDL on human monocyte‐macrophages , 2001, FEBS letters.

[45]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[46]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[47]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[48]  K. Feingold,et al.  In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[49]  S. Young,et al.  Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein* , 1999, The Journal of Biological Chemistry.

[50]  W. Edwards,et al.  Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. , 1994, The American journal of cardiology.

[51]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[52]  S. Fowler.  Characterization of foam cells in experimental atherosclerosis. , 2009, Acta medica Scandinavica. Supplementum.